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Studies of various animal models have made a 
substantial contribution to the recent progress in 
understanding the molecular and cellular basis of 
neurodegenerative disorders. Modelling of neuro-
degeneration by genetic alteration of laboratory 
animals became one of the most powerful tools of 
modern  experimental  neurology.  The  crucial 
event in pathogenesis of neurodegenerative dis-
eases known as synucleinopathies is modification 
of  α-synuclein  metabolism  caused  by  missense 
mutations, increased expression of the gene, or 
impaired degradation or intracellular compart-
mentalisation of the protein. Therefore, manipu-
lations with expression of α-synuclein in labora-
tory animals were widely used for creating models 
of these diseases. In the present review we discuss 
strong and weak sides of such models, what has 
been already learned from studies of these ani-
mals and what types of models might be useful to 
further our knowledge about pathogenesis of dif-
ferent synucleinopathies.
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INTRODUCTION
In  the  last  decade  substantial  progress  has  been 
achieved in understanding molecular and cellular 
events  associated  with  neurodegeneration.  The 
pivotal role of particular proteins in the develop-
ment of specific pathologies has been revealed, for 
example, amyloid β-protein precursor (APP) and 
tau for Alzheimer's disease, superoxide dismutase 
(SOD)  for ALS  and  huntingtin  for  Huntington's 
disease. The crucial moment for studies of aetiol-
ogy and pathogenesis of Parkinson's disease (PD) 
was  the  revealing  of  α-synuclein  as  a  causative 
factor for both familial and idiopathic forms of this 
disease (Polymeropoulos et al., 1997; Spillantini et 
al., 1997). Further studies demonstrated that mis-
handling of this protein by various types of neu-
rons or glial cells is associated with several neuro-
logical disorders, including dementia with Lewy 
bodies (DLB), multiple system atrophy (MSA) and 
certain others. These diseases were coalesced into 
a  new  group  named  synucleinopathies  (Goedert 
and  Spillantini,  1998;  Spillantini  and  Goedert, 
2000; Galvin et al., 2001; Marti et al., 2003). The 
major  histopathological  feature  of  synucleinopa-
thies is accumulation of fibrillated α-synuclein that 
forms  characteristic  inclusions  in  the  perikaria, 
neurites and, sometimes, nuclei of affected cells. 
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Accumulation and aggregation of α-synuclein can 
be  caused  by  many  factors,  including  increased 
expression due to duplication or triplication of the 
gene, reduced degradation of the protein or its dis-
turbed  transport  to  synaptic  terminals,  where 
α-synuclein normally resides and functions. Rare 
missense mutations (A53T, A30P and E46K have 
been identified so far) affect intrinsic properties of 
α-synuclein; this could lead to pathology associ-
ated with familial forms of PD. However, for idio-
pathic  forms  of  PD  and  other  synucleinopathies 
that comprise the majority of cases, some external 
factors should trigger changes of the metabolism of 
normal α-synuclein protein. 
   Although inclusions are the most prominent 
feature of synucleinopathies, their role in dys-
function  and  death  of  neurons  is  not  clear. A 
growing body of evidence suggests that interme-
diates  of  α-synuclein  aggregation,  oligomers 
and  protofibrils,  but  not  final  products  of  this 
process, fibrils, are toxic for neurons (reviewed 
in  Caughey  and  Lansbury,  2003;  Dev  et  al., 
2003; Fink, 2006; Uversky, 2007). Another key 
and still unanswered question is why particular 
cell populations are more sensitive than others to 
α-synuclein pathology. Most importantly, poor 
understanding of the mechanisms of α-synuclein-
induced  neurodegeneration  precludes  develop-
ment of therapies that might target dysfunction 
of this protein. 
   Neurodegeneration is an extremely compli-
cated process and clear understanding molecular 
and cellular events leading to pathology requires 
combination of clinical and experimental stud-
ies. Although in vitro and tissue culture studies 
were quite useful for revealing certain intracel-
lular  mechanisms  of  neurodegeneration,  only 
modelling of particular types of neurodegenera-
tive processes in laboratory animals could pro-
vide a tool for experimental studies in the con-
text  of  the  whole  organism.  Various  animal 
models  were  used  for  studying  synucleinopa-
thies but the most obvious way of creating such 
models - by genetic manipulation of α-synuclein 
expression - appeared to be not the most straight-
forward and fruitful. In this review we describe 
what  has  been  achieved  in  these  studies  and 
what questions are waiting for better models that 
should help in finding comprehensive answers.
Pan-Neuronal Expression of α-Synuclein 
in Transgenic Mice 
The first attempt to model synucleinopathy in trans-
genic mice was made by Masliah and colleagues at 
the turn of the century (Masliah et al., 2000). A 
relatively  strong,  although  non-specific  PDGFβ 
gene promoter was used to control expression of 
the  wild  type  human  α-synuclein.  This  allowed 
achieving relatively high levels of human protein 
expression in the nervous system of five indepen-
dent  mouse  lines.  Progressive  accumulation  of 
cytoplasmic and nuclear inclusions in neurons of 
deep cortical layers, CA3 area of the hippocampus, 
ophthalmic bulb and, rarely, substantia nigra, was 
observed  in  all  these  mice  from  the  age  of  two 
months. These inclusions were positive for ubiq-
uitin and human α-synuclein but not endogenous 
mouse α-synuclein. In contrast to Lewy bodies and 
other inclusions characteristic for human synucle-
inopaties, inclusions in transgenic mouse neurons 
consisted  of  amorphous  aggregates  and  not 
α-synuclein  fibrils  (Masliah  et  al.,  2000;  2001). 
Only animals of line D with the level of human 
α-synuclein  expression  approximately  five  times 
higher than in other lines developed pathology - at 
the  age  of  12  months  these  animals  displayed  a 
marked decrease of the level and activity of tyrosine 
hydroxylase in the striatum, and motor dysfunction 
that could be revealed in a rotarod test. However, 
no loss of dopaminergic neurons was found in the 
substantia  nigra  of  these  mice  (Masliah  et  al., 
2000). Further studies of line D in several laborato-
ries revealed other but usually subtle changes of the 
phenotype (Hashimoto et al., 2001; 2004; Masliah 
et al., 2001; 2005; Klucken et al., 2004; Winner et 
al.,  2004;  2008;  Bar-On  et  al.,  2006),  including 
negative effect of human αsynuclein expression on 
survival but not proliferation of neuronal precursor 
cells (Winner et al., 2004; 2008). Interestingly, co-
expression of α-synuclein and β-amyloid peptides 
had substantial effect on pathological changes in 
the  nervous  system  of  double  transgenic  mice. 
Fibrillated human α-synuclein was found in neu-
ronal inclusions along with amorphous protein, and 
progressive degeneration of synapses and neurons 
of cholinergic system developed in the brain of age-
ing animals (Masliah et al., 2001). Therefore, neu-
ronal pathology in double transgenic mice resem-
bled  pathology  characteristic  to  dementia  with TRANSGENIC ANIMALS MODELS OF SYNUCLEINOPATHIES 331
Lewy bodies and Lewy body variant of Alzheimer's 
disease.  In  another  laboratory  PDGFβ  promoter 
was used to regulate expression of either wild type 
or A53T mutant human α-synuclein (Sharon et al., 
2001; 2003). Both studies focused on interaction of 
α-synuclein with polyunsaturated fatty acids, and 
although progressive accumulation of soluble oli-
gomers in the brain of transgenic mice was observed 
(Sharon  et  al.,  2003),  changes  of  the  phenotype 
have not been reported for any of several indepen-
dent lines of these transgenic animals. 
      High  levels  of  α-synuclein  expression  in  the 
majority of neurons throughout the nervous system 
of transgenic mice was also achieved in a number 
of laboratories by using a prion protein (PrP) gene 
promoter  of  either  hamster  (Gomez-Isla  et  al., 
2003; Fortin et al., 2004) or mouse origin (Giasson 
et al., 2002; Lee et al., 2002; Gispert et al., 2003). 
Several animal lines expressing various levels of 
wild type or mutant (A53T or A30P) α-synuclein 
were  generated  in  each  laboratory.  Pathological 
phenotypes were often observed in mice expressing 
mutant variants of the protein while animals express-
ing in their neurons even high levels of wild type 
protein  were  completely  spared  of  pathology 
(Giasson et al., 2002; Lee et al., 2002; Gispert et 
al., 2003; Gomez-Isla et al., 2003). However, even 
with mutant proteins results were not very consis-
tent. Homozygous transgenic mice from two inde-
pendent lines expressing A53T human α-synuclein 
developed motor dysfunction with paralysis that led 
to eventual death at the age of approximately 16 
months. However, hemizygous animals from one of 
these lines never developed any sign of pathology, 
while the onset of pathology for hemizygous mice 
from  another  line  was  around  22-28  months 
(Giasson et al., 2002). 
   Similar results were reported by Lee et al. (2002) 
who also observed pathological phenotype in trans-
genic mice expressing A53T human α-synuclein. In 
studied  mouse  lines  an  inverse  correlation  was 
found between the level of this transgene expres-
sion  and  the  onset  of  the  development  of  lethal 
neuronal  pathology.  Histological  changes  that 
included  α-synuclein-positive  and  ubiquitin-posi-
tive  inclusions  in  neuronal  cell  bodies  and  pro-
cesses, damaged neuronal mitochondria, and apop-
totic death of neurons were observed in many areas 
of the nervous system (Lee et al., 2002; Martin et 
al., 2006). However, as in the previously described 
study (Giasson et al., 2002), these changes were 
most common for motoneurons of the spinal cord. 
The  clinical  manifestation  of  the  pathology  was 
mainly caused by dysfunction and death of these 
neurons. The dopaminergic nigrostriatal system of 
these  mice  was  generally  unaffected,  although 
changes  of  dopamine  neurotransmission  were 
reported in the later study (Unger et al., 2006). No 
pathology  was  found  in  mice  with  low  level  of 
A53T  or  high  level  of  either  wild  type  or A30P 
human α-synuclein expression (Lee et al., 2002). 
   Different results were obtained in another labora-
tory that used PrP promoter-driven expression of 
human α-synuclein transgenes (Gomez-Isla et al., 
2003). Five lines expressing different forms of this 
protein were produced but in four of them expres-
sion of wild type or A53T or A30P protein did not 
trigger pathology in transgenic mice even at the age 
of 20 months although expression levels of human 
proteins were substantially higher than the level of 
endogenous mouse α-synuclein. Only mice from 
the  line  Tg5093  with  the  highest  level  of A30P 
α-synuclein expression displayed pathological phe-
notype - homozygous animals developed progres-
sive motor dysfunction from the age of 4-7 months, 
whereas much later onset (8-16 months) was typi-
cal for hemizygous animals. However, no patho-
logical  inclusions,  deposits  or  other  evidence  of 
human α-synuclein aggregation were found even in 
homozygous Tg5093 mice that accumulated large 
amounts of this protein in their neurons and devel-
oped obvious clinical signs of pathology. A wide-
spread gliosis was the only histopathological mani-
festation  of  degenerative  changes  in  the  nervous 
system  of  these  mice.  Although  minimal  if  any 
changes were observed in the nigrostriatal system, 
dopaminergic neurons of substantia nigra of Tg5093 
animals were more sensitive to the toxic effect of 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) but not rotenone (Gomez-Isla et al., 2003; 
Nieto et al., 2006). Similar observations were made 
by  another  group  -  expression  of  A53T  human 
α-synuclein induced progressive motor dysfunction 
without any signs of human α-synuclein aggrega-
tion  in  the  nervous  system  of  transgenic  mice 
(Gispert  et  al.,  2003).  This  phenotype  was  not 
noticed in mice of a line that expressed lower levels 
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expression of endogenous mouse α-synuclein by 
cross breeding of these mice with α-synuclein null 
mutant mice, resulted in spinal motoneuron dys-
function and paralyses at around 16 months of age 
(Cabin et al., 2005). This result might suggest that 
at least for some neuronal populations expression 
of α-synuclein during development makes them 
protected from certain neurotoxic insults in post-
natal period. 
   A promoter of the mouse Thy-1 gene was also 
widely used for generation of mice with pan-neu-
ronal  expression  of  α-synuclein.  In  contrast  to 
unsuccessful  attempts  with  PrP  promoter-driven 
expression,  Thy-1  promoter  was  associated  with 
reproduction  of  certain  pathological  changes  in 
mice expressing not only mutant but also wild type 
human  α-synuclein  (van  der  Putten  et  al.,  2000; 
Rockenstein  et  al.,  2002;  Fleming  et  al.,  2004; 
Chandra et al., 2005). From the age of 3 months 
mice expressing either wild type or A53T human 
α-synuclein developed progressive motor dysfunc-
tion accompanied by pathological changes in syn-
apses, axons and cell bodies of neurons, predomi-
nantly  motoneurons  of  the  spinal  cord  and  the 
brainstem (van der Putten et al., 2000). Relatively 
early  changes  in  the  sensory  and  motor  systems 
were also revealed by various behavioural tests in 
another transgenic mouse line but no pathological 
inclusions were found in neuronal cell bodies or 
processes of these mice (Rockenstein et al., 2002; 
Fleming et al., 2004). No substantial dysfunction of 
dopaminergic neurons of the substantia nigra was 
observed, which is not surprising because it is well 
known that expression levels of Thy-1 promoter-
driven transgenes in these neurons is usually quite 
low.  Nevertheless,  further  studies  of  these  mice 
revealed increased sensitivity to subtoxic doses of 
MPTP  (Song  et  al.,  2004),  paradoxical  effect  of 
3,4-L-dihydroxyphenylalanine  (L-DOPA),  abnor-
mal  responses  to  apomorphine  and  amphetamine 
(Fleming  et  al.,  2006),  and  stimulation  of 
α-synuclein aggregation by paraquat (Fernagut et 
al., 2007), which all might reflect sub-pathological 
changes in their nigrostriatal system. 
   In contrast to transgenic mice described above, in 
heterozygous animals from several lines produced 
in another laboratory, accumulation of either wild 
type or A30P human α-synuclein in neuronal cell 
bodies and neurites was accompanied by its aggre-
gation, as revealed by biochemical analysis (Kahle 
et al., 2000; 2001). However, only in one of these 
lines  aggregation  and  hyperphosphorylation  of 
α-synuclein lead to the development of intracellular 
inclusions,  dysfunction  of  motor  and  cognitive 
functions,  and  astrocytosis  predominantly  in  the 
spinal cord and the brainstem. The onset of these 
changes was substantially earlier for homo- than for 
hemizygous  animals  (Neumann  et  al.,  2002; 
Freichel et al., 2007). Changes of the activity of 
certain mitochondrial enzymes (Poon et al., 2005) 
and increased tau phosphorylation (Frasier et al., 
2005) were also found in the nervous system of 
these  mice  but  sensitivity  of  their  dopaminergic 
neurons to MPTP toxicity was not altered (Rathke-
Hartlieb et al., 2001). 
   Several mouse lines with roughly similar levels 
of expression (5-10 times higher than the level of 
endogenous α-synuclein expression) of wild type, 
A30P  or A53T  human  α-synuclein  or  wild  type 
mouse  α-synuclein  under  control  of  Thy-1  pro-
moter were used to compare the ability of these 
proteins to trigger pathological changes (Chandra 
et al., 2005). Age-related progressive neurodegen-
eration with α-synuclein aggregation, astrocytosis, 
spinal  motoneuron  loss  and  paralyses  of  limbs 
were observed in mice expressing either form of 
human protein. However, the penetrance of pheno-
type development at 16 months of age was over 
70%  in  lines  expressing  mutant  forms  and  only 
16%  in  lines  expressing  wild  type  human 
α-synuclein (Chandra et al., 2005; Gallardo et al., 
2008). Pathology did not develop in mice express-
ing even high levels of wild type mouse α-synuclein 
(Chandra et al., 2005). 
   Recently, consequences of Thy-1 promoter-driven 
expression  of  a  new  type  of  modified  human 
α-synuclein have been checked in transgenic mice. 
A  mutation  that  results  in  the  substitution  of 
tyrosine to cysteine at position 39 of α-synuclein 
molecule has not been found in association with 
any  of  hereditary  synucleinopathies  but  in  vitro 
studies have demonstrated that the ability of Y39C 
α-synuclein  to  form  dimers  via  disulfide  bonds 
substantially increases its propensity to aggregate 
and the ability to cause cytotoxicity. Consequently, 
even a relatively low level of transgene expression 
(approximately 150% of the level of endogenous 
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α-synuclein oligomers, formation of intraneuronal 
inclusions and apoptotic death of neurons (Zhou et 
al.,  2008).  These  molecular  and  cellular  changes 
were followed by progressive decline of motor and 
cognitive functions in ageing mice. However, as for 
the majority of mouse lines discussed above, sub-
stantia nigra neurons were not affected in these mice 
and pathological changes were restricted to the cere-
bral cortex and spinal cord. 
   Studies of transgenic mouse lines with pan-neu-
ronal  expression  of  human  α-synuclein  isoforms 
made substantial contribution to our understanding 
molecular mechanisms of the development of synu-
cleinopathies. For instance, it has been clearly dem-
onstrated  that  expression  of  wild  type  human 
α-synuclein  could  trigger  neuronal  pathology  but 
only when the level of transgene expression in neu-
rons is substantially higher than the level of endog-
enous mouse α-synuclein expression in these cells. 
Even lines with high levels of human wild type pro-
tein expression show late onset and low penetrance 
of pathology suggesting that for the development of 
pathological changes in the nervous system of these 
mice accumulation of wild type human α-synuclein 
should be complemented by some additional uniden-
tified internal and/or environmental factors. These 
results are in agreement with analysis of familiar 
forms of synucleinopathies caused by duplications 
or triplications of α-synuclein gene that also revealed 
incomplete penetrance of the disease for carriers of 
these mutations (Singleton et al., 2003; Farrer et al., 
2004). The absence of pathology in mice expressing 
high levels of mouse α-synuclein is consistent with 
in vitro data that demonstrated lower propensity to 
aggregate  for  mouse  protein  compared  to  human 
protein (reviewed in Uversky and Fink, 2002; Fink, 
2006; Uversky, 2007). This also suggests that the 
development  of  pathology  could  not  be  triggered 
simply  by  enhancing  a  normal  function  of 
α-synuclein. Another clear conclusion that could be 
drawn  from  the  analysis  of  the  above  described 
mouse lines is that the expression level threshold 
required  for  triggering  pathology  is  substantially 
lower  for  proteins  carrying  Parkinson's  disease-
associated  amino  acid  substitutions  than  for  wild 
type human protein. This could be considered as a 
direct experimental confirmation of a causative role 
for  corresponding  gene  mutations  in  aetiology  of 
familial forms of Parkinson's disease. 
   Aggregation of human α-synuclein is common for 
transgenic animals that developed clinical signs of 
neurological  pathology  although  in  several  lines 
such pathology was not accompanied by aggrega-
tion of this protein and, conversely, mice from other 
lines with multiple α-synuclein-positive inclusions 
in their nervous system did not develop any pathol-
ogy.  Therefore,  studies  of  these  mouse  models 
failed to clarify the role of α-synuclein aggregation 
in the development of clinical signs of pathology. 
Even those of transgenic mouse lines that displayed 
obvious  progressive  neurological  phenotype  with 
histopathological changes similar to changes typi-
cal for synucleinopathies had one serious disadvan-
tage as models for these diseases - localisation of 
pathology. In the majority of cases, the spinal cord 
was the most affected region of the nervous system 
of  these  mice,  and  the  observed  phenotypical 
changes  mainly  reflected  damage  or  loss  of 
motoneurons and their axons, while spinal pathol-
ogy is not a common feature of human synucle-
inopathies. Further studies are required to reveal if 
this was the result of high levels of expression of all 
utilized  transgenes  in  spinal  motoneurons  or  an 
increased sensitivity of these cells to toxic effects of 
human α-synuclein. 
Cell Type Specific Expression of α-Synuclein 
in Transgenic Mice 
A number of attempts were made to create trans-
genic mouse models of a particular synucleinopa-
thy. For creation of an animal model of PD several 
laboratories expressed various forms of α-synuclein 
specifically  in  dopaminergic  neurons.  Similarly, 
specific expression of this protein in oligodendro-
cytes was applied for modelling of MSA. 
Expression in Dopaminergic Neurons
A common approach for producing mice with dys-
function of the dopaminergic system was specific 
expression of human α-synuclein in dopaminergic 
neurons using tyrosine hydroxylase (TH) promoter. 
Studies of the first sets of such transgenic mouse 
lines generated independently in two laboratories 
produced  rather  disappointing  results.  Animals 
expressing  either  wild  type  or  mutant  (A53T  or 
A30P) human α-synuclein did not develop motor or 
other behavioural dysfunction, and no histopatho-
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systems despite accumulation of the human protein 
in cell bodies and processes of dopaminergic neu-
rons (Matsuoka et al., 2001; Rathke-Hartlieb et al., 
2001). Also, no changes were found in striatal dop-
amine metabolism, number of dopaminergic neu-
rons in the substantia nigra, or their sensitivity to 
the toxic effect of MPTP (Matsuoka et al., 2001; 
Rathke-Hartlieb et al., 2001; Manning-Bog et al., 
2003). Although paraquat treatment induced aggre-
gation of the wild type or mutant form of human 
α-synuclein in dopaminergic neurons, they were 
resistant  to  the  toxic  effect  of  this  herbicide 
(Manning-Bog  et  al.,  2003).  No  pathological 
changes were revealed in studies of several other 
more  recently  generated  mouse  lines  with  TH 
promoter-driven expression of human α-synuclein 
(Wakamatsu et al., 2007; 2008).
   Changes in the dopaminergic system were also 
minimal in a line of mice expressing wild type 
human α-synuclein under control of TH promoter 
that was produced in another laboratory (Richfield 
et  al.,  2002).  However,  mice  expressing  under 
control of this promoter a double mutant human 
α-synuclein  (with  both  A53T  and  A30P  amino 
acid  substitutions)  developed  a  motor  deficit 
accompanied by progressive axonal and synaptic 
pathology, changes of dopamine metabolism, dys-
function of ubiquitin-proteasome system, and loss 
of neurons in their nigrostriatal system (Richfield 
et al., 2002; Thiruchelvam et al., 2004; Chen et 
al., 2006). Dopaminergic neurons of the substantia 
nigra were more sensitive to combined toxicity of 
herbicides paraquat and maneb but did not have 
pathological  inclusions  or  aggregates  of 
α-synuclein (Thiruchelvam et al., 2004). Different 
results  were  obtained  in  another  laboratory  that 
produced  transgenic  mice  expressing  the  same 
double mutant human α-synuclein under control 
of  three  different  promoters,  including TH  pro-
moter. These mice did not develop any pathologi-
cal phenotype, and only progressive structural and 
functional changes of mitochondria were found in 
their neurons. Neither pathological inclusions, nor 
loss of neurons or their synapses, nor astrogliosis 
was observed (Maskri et al., 2004; Stichel et al., 
2007).  It  is  not  clear  why  results  of  these  two 
laboratories are so contradictory. 
   Truncated α-synuclein species lacking C-terminal 
sequences have increased propensity to aggregate 
in vitro and are abundant in pathological inclusions 
found in brains of patients suffering from synucle-
inopathies.  Nevertheless,  aggregated  α-synuclein 
was  not  found  in  dopaminergic  neurons  of  mice 
expressing a C-terminally truncated, α1-130, vari-
ant of human protein under control of TH promoter 
(Wakamatsu et al., 2008). As in the case of mice 
described  above  (Richfield  et  al.,  2002),  in  the 
absence of aggregates these mice still developed 
selective loss of dopaminergic neurons in the sub-
stantia nigra, reduced striatal dopamine level and, 
consequently,  motor  dysfunction.  However,  these 
changes  were  not  progressive  and  neuronal  loss 
took place soon after activation of transgene expres-
sion at the early embryonic stage (Wakamatsu et 
al.,  2008).  In  contrast,  mice  with  TH  promoter-
driven expression of another C-terminally truncat-
ed, α1-120, variant of human α-synuclein devel-
oped  progressive  decrease  of  locomotor  activity, 
which correlated with decreasing level of striatal 
dopamine and formation of pathological inclusions 
in  dopaminergic  neurons  in  the  substantia  nigra 
(Tofaris et al., 2006). No loss of these neurons was 
revealed, although the recent study suggested that 
their sensitivity to stress could be increased (Tofaris 
et al., 2006; Michell et al., 2007). 
   In summary, expression of α-synuclein in trans-
genic mice under control of TH promoter turned to 
be  inefficient  for  creating  mouse  models  of  PD. 
Triggering of some pathological changes in dop-
aminergic neurons was achieved only when artifi-
cially engineered mutant forms of human protein 
were used but the whole spectrum of PD pathology 
has not been reproduced in any of these models. 
The most probable explanation of these failures is 
the low level of TH promoter-regulated expression 
of  transgenes.  Because  of  this  low  expression, 
accumulation of exogenous α-synuclein in mouse 
dopaminergic  neurons  does  not  reach  the  level 
required for triggering pathological changes. It is 
well documented that rodent dopaminergic neurons 
are  more  resistant  than  human  neurons  to  toxic 
drugs causing PD, like MPTP. It is feasible that a 
pathological threshold level of α-synuclein is also 
substantially  higher  for  mouse  neurons  than  for 
human neurons and, therefore, successful model-
ling of pathology in mice requires stronger dop-
aminergic neuron-specific promoters for expression 
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Expression in Oligodendrocites
Attempts to create mouse models of MSA were 
much more successful. The approach for modelling 
MSA was based on ectopic expression of wild type 
human  α-synuclein  in  mouse  oligodendrocytes 
because  α-synuclein-positive  inclusions  in  these 
cells are the major histopathological hallmarks of 
this  idiopathic  disease.  Aggregation  and  hyper-
phosphorylation of α-synuclein, and formation in 
the perinuclear area of oligodenrocytes of inclu-
sions  that  resembled  inclusions  in  oligodendro-
cytes  of  MSA  patients  were  achieved  in  several 
mouse  lines  with  transgene  expression  regulated 
by  oligodendrocyte-specific  proteolipid  protein 
(PLP) gene promoter (Kahle et al., 2002). However, 
these animals did not develop any motor dysfunc-
tion, and degeneration of neurons or axons was not 
noticed in their nervous system, probably due to 
low levels of transgene expression. Nevertheless, 
they  appeared  to  be  more  sensitive  to  oxidative 
stress because a mitochondrial inhibitor, 3-nitrop-
ropionic  acid  (3-NP),  triggered  development  of 
substantially more severe neurological pathology 
in these transgenic mice than in control wild type 
mice (Stefanova et al., 2005). Importantly, regional 
localisation  of  neurodegeneration  and  atrophy 
within the brain of transgenic mice closely resem-
bled  localisation  of  pathology  typical  for  MSA. 
These changes along with widespread astrogliosis 
and microglia activation led to gradual decline of 
animal motor performance in various behavioural 
tests (Stefanova et al., 2005; 2007a,b,c). 
      Another,  2',3'-cyclic  nucleotide-3'-phosphodi-
esterase (CNP), gene promoter also produced rela-
tively low total brain level of human α-synuclein 
expression  in  transgenic  mice,  but  because  this 
expression was restricted to oligodendrocytes, the 
level of ectopic protein in these cells was substan-
tially higher than the level of endogenous mouse 
α-synuclein (Yazawa et al., 2005). Aggregation of 
human α-synuclein and progressive accumulation 
of its fibrils observed in oligodendrocytes led to 
their degeneration and death as well as autophago-
cytosis  of  axonal  myelin  sheets.  Interestingly, 
endogenous α-synuclein was also involved in the 
development of pathological changes in neurons of 
these mice - abnormal accumulation of mouse pro-
tein was found in axons and presynaptic terminals. 
The outcome of above changes was the loss of both 
glial and neuronal cells in many regions of the brain 
of  transgenic  mice  and  the  impairment  of  their 
motor behaviour (Yazawa et al., 2005). 
      Pathological  phenotype  was  even  more  pro-
nounced  in  a  line  of  transgenic  mice  expressing 
very high level of human α-synuclein under control 
of the myelin basic protein gene promoter (Shults et 
al., 2005). In contrast to mice from other lines with 
lower levels of transgene expression that lived lon-
ger than 18 months, all mice from this line devel-
oped severe neurological alterations at 2-4 months 
of age, resulting in death at the age of 6 months. 
Histological pathology in the brain of affected ani-
mals included astrogliosis, and structural changes 
of  axons  and  their  myelin  sheets  followed  by 
degeneration of these structures. It has been sug-
gested that the above changes were triggered by 
dysfunction of oligodendrocytes, which in turn was 
caused  by  aggregation  of  human  α-synuclein  in 
these cells and formation of inclusions similar to 
inclusions seen in oligodendrocites of MSA patients 
(Shults et al., 2005). 
   Why did overexpression of α-synuclein in rele-
vant cell populations produce respectable models of 
MSA but not PD pathology? It is feasible that neu-
rons expressing α-synuclein during the embryonic 
period become "tolerant" to accumulation of this 
protein at the later stages of development. In con-
trast, oligodendrocytes that normally express very 
little, if any, α-synuclein are much more sensitive 
to  forced  accumulation  of  this  protein,  which 
resembles the situation with ectopic expression of 
α-synuclein in invertebrates neurons (see below). 
Nevertheless it should be noted, that low levels of 
exogenous α-synuclein expression are still not suf-
ficient for triggering pathology in oligodendrocytes, 
i.e., a threshold level of expression and accumula-
tion should be reached. In this aspect, it would be 
interesting to reveal if mutant forms of α-synuclein 
that  induced  pathology  in  neurons  much  more 
effectively  than  wild  type  α-synuclein  would  be 
also more effective in triggering pathology in oligo-
dendrocytes where transport of this protein from 
cell body to presynaptic terminals is not an issue.
Invertebrate Models of Synucleinopaties 
and the Role of Endogenous α-Synuclein 
Substantial pathological changes were observed in 
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α-synuclein  but  lacking  endogenous  mouse 
α-synuclein  (Cabin  et  al.,  2005;  Chandra  et  al., 
2005; Tofaris et al., 2006; Gallardo et al., 2008). 
Although only one study directly demonstrated that 
the severity of pathology increases at α-synuclein 
null background (Cabin et al., 2005), it has been 
suggested that the endogenous protein has neuro-
protective function(s). A possible scenario is that 
expression of endogenous α-synuclein in develop-
ing embryonic neurons makes them tolerant to this 
protein, e.g., certain intracellular pathways become 
permanently  active  (or  permanently  inactive), 
which helps these cells to combat, to some extent, 
increased expression of this protein at later stages 
of  life.  In  contrast,  neurons  that  never  express 
α-synuclein  during  development  and  therefore 
never get prompted to develop such defense mecha-
nisms become vulnerable to this protein. Importantly, 
the vulnerability to α-synuclein toxicity does not 
equate  with  increased  sensitivity  to  other  toxic 
insults;  conversely,  increased  resistance  to 
α-synuclein  toxicity  does  not  necessarily  make 
cells generally more robust. Moreover, a particular 
combination of active/inactive signalling pathways 
might increase sensitivity to one and resistance to 
another type of toxic factor (see below). However, 
other mechanisms of neuroprotection by endoge-
nous α-synuclein could also be suggested and our 
current knowledge is far from sufficient in choos-
ing between many possible explanations. 
   However, the absence of endogenous α-synuclein 
could  explain  why  invertebrates  that  lack  any 
synuclein-like proteins readily develop pathologi-
cal  features  typical  for  human  synucleinopathies 
upon  ectopic  expression  of  α-synuclein  in  their 
neurons. Expression of wild type, A53T or A30P 
human α-synuclein in transgenic Drosophila mela-
nogaster flies resulted in aggregation of α-synuclein, 
formation  of  intracellular  inclusions,  progressive 
loss of dopaminergic neurons and changes of loco-
motor  behaviour  (Feany  and  Bender,  2000). 
Similarly, loss of dopaminergic neurons and their 
axons, reduction of dopamine level and motor dys-
function  were  characteristic  for  transgenic 
Caenorhabditis  elegans  worms,  expressing  wild 
type or mutant human α-synuclein (Lakso et al., 
2003; Kuwahara et al., 2006).
   Neither neuronal loss nor α-synuclein oligomers, 
fibrils or inclusions were found in the nervous sys-
tem of transgenic flies expressing a deletion mutant 
of  human  α-synuclein  (lacking  an  internal  frag-
ment between amino acids 71 and 82) that shows 
decreased propensity to aggregate in vitro. In con-
trast, expression of a C-terminally truncated pro-
tein led to its aggregation into large intraneuronal 
inclusions  and  neuronal  death  (Periquet  et  al., 
2007).  These  results  suggested  that  aggregation 
and inclusion formation are required for neurotoxic 
effects  of  ectopically  expressed  α-synuclein. 
However, studies of another line of transgenic flies 
demonstrated  that  co-expression  of  a  chaperon, 
Hsp70, could rescue dopaminergic neurons from 
α-synuclein-induced  death  but  has  no  effect  on 
α-synuclein aggregation or inclusion formation in 
surviving neurons (Auluck et al., 2002). Therefore, 
studies  of  transgenic  flies,  as  described  in  the 
above studies of transgenic mice, failed to resolve 
ambiguities  about  the  role  of  aggregation  in 
α-synuclein-induced neurotoxicity.
Protective Function of Endogenous α-Synuclein 
and its Role in the Development 
of Neurodegeneration
In the healthy nervous system α-synuclein is loca-
lised  nearly  exclusively  in  presynaptic  terminal, 
suggesting that it has important functions in this 
neuronal  compartment  (Maroteaux  et  al.,  1988; 
Maroteaux and Scheller, 1991; Jakes et al., 1994). 
It  has  been  suggested  that  α-synuclein  plays  an 
important  role  in  synaptoprotection  (Chandra  et 
al., 2005) and, therefore, α-synuclein dysfunction 
could lead to degeneration of synapses followed by 
retrograde death of neurons. Increased expression 
of α-synuclein or expression of mutant forms trig-
ger aggregation and compromise axonal trafficking 
of this protein (Saha et al., 2004). Consequently, 
α-synuclein stacks in the neuronal cell body, and 
its  synaptic  pool  gets  gradually  depleted,  which 
makes synapses progressively vulnerable to vari-
ous  stress  and  other  environmental  factors. 
According to this hypothesis the loss of protective 
function of endogenous α-synuclein is a substan-
tial if not crucial event in the development of neu-
rodegeneration in synucleinopathies. Another obvi-
ous conclusion is that animals lacking α-synuclein 
should  develop  synaptic  pathology  followed  by 
axonal  and,  finally,  neuronal  degeneration. 
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particularly if one takes into consideration that syn-
apses and neurons of invertebrates survive perfectly 
well and function without α-synuclein or any other 
synuclein-like proteins. Indeed, mice with targeted 
inactivation  of  α-synuclein  gene  independently 
produced in several laboratories did not display any 
signs of neurodegeneration, although slight abnor-
malities  of  synaptic  and  mitochondrial  functions 
and reduced numbers of neurons in certain popula-
tions have been reported (Abeliovich et al., 2000; 
Cabin et al., 2002; Dauer et al., 2002; Chandra et 
al., 2004; Robertson et al., 2004; Ellis et al., 2005). 
Moreover, animals supplied by Harlan UK to many 
laboratories as C57Bl6 wild type mice were found 
to  carry  a  homozygous  deletion  of  a  locus  that 
includes the whole α-synuclein gene (Specht and 
Schoepfer, 2001). 
   A possible explanation for the absence of notice-
able alterations in the nervous system of α-synuclein 
null mutant mice is a functional compensation by 
two other closely related members of the synuclein 
family, β-synuclein and γ-synuclein. However, this 
idea got a substantial blow when no obvious phe-
notypical changes were observed in double (α/γ 
(Robertson et al., 2004) or α/β (Chandra et al., 
2004)) or even in triple (our unpublished observa-
tions) synuclein null mutant mice. How is it pos-
sible that mouse neurons are so indifferent to the 
presence  of  such  an  evolutionary  conserved  and 
highly  expressed  protein?  It  could  be  suggested 
that developing embryonic neurons of null mutant 
mice switch on certain intrinsic mechanisms that 
compensate  for  the  absence  of  synucleins. 
Activation of these mechanisms allows neurons to 
survive during critical developmental periods and 
function in adult nervous system. Although there is 
no experimental data that could give a clue about 
the nature of these intracellular mechanisms and 
their  relationship  with  mechanisms  that  confer 
neurons tolerant to α-synuclein (see above), one 
may speculate that activation of compensatory pro-
survival processes/ pathways could make neurons 
less sensitive to certain toxic insults. Indeed, dop-
aminergic neurons of substantia nigra pars com-
pacta of α-synuclein and γ-synuclein null mutant 
mice were found to be resistant to toxic effects of 
MPTP, paraquat, 3-NP and malonate (Dauer et al., 
2002; Drolet et al., 2004; Robertson et al., 2004; 
Fornai et al., 2005; Klivenyi et al., 2006; and our 
unpublished  data).  However,  the  same  neurons 
might be more sensitive to other factors or chang-
es  of  intracellular  metabolism,  for  instance  to 
overexpression of α-synuclein later in the devel-
opment (see above). Another example is acceler-
ated development in mice lacking two members of 
the synuclein family, α-synuclein and β-synuclein, 
of neurodegeneration triggered by the absence of 
synaptic  co-chaperone  CSPα  (Chandra  et  al., 
2005).  Moreover,  increased  expression  of  func-
tional α-synuclein in CSPα null mutant mice res-
cued  degeneration  of  synapses.  These  results 
directly demonstrated that α-synuclein could pro-
tect synapses and neurons from particular patho-
logical processes.    
   Interestingly, substantial impairment of synaptic 
function was observed in the nigrostriatal system of 
ageing α-synuclein null mutant animals (our unpub-
lished data). This suggests that although dopamin-
ergic  neurons  are  able  to  compensate  for  the 
absence of α-synuclein, this requires mobilisation 
of  other  protective  systems,  whose  efficiency 
declines in an ageing organism. As the result, neu-
ronal  compartments  that  are  normally  rich  in 
α-synuclein,  first  of  all  presynaptic  terminals, 
become unprotected, which leads to their dysfunc-
tion and degeneration. 
   A growing body of evidence suggests that deple-
tion of the synaptic pool of α-synuclein contributes 
to the development of neurodegeneration in patients 
and in animal models of synucleinopathies but it is 
not clear how substantial this contribution could be. 
Currently  available  tools  are  not  adequate  for 
approaching the problem - new animal models are 
desperately needed that will allow tightly regulated 
conditional inactivation of α-synuclein expression 
in vivo. This will eliminate the impact of develop-
mental compensation and should clarify the role of 
endogenous α-synuclein in the adult, ageing and 
degenerating nervous system.
CONCLUSIONS
Studies  of  animals  with  modified  expression  of 
α-synuclein produced a wealth of data that sub-
stantially improved our understanding of aetiology 
and  pathogenesis  of  synucleinopaties.  However, 
many important questions still remain unanswered 
due to the complexity of the process and relative V.L. BUCHMAN & N. NINKINA 338
simplicity of animal models created so far. New 
more sophisticated models with tightly regulated 
and conditional expression of α-synuclein as well 
as  other  members  of  the  family  are  urgently 
required. To get better juice one should squeeze 
better fruits.
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